You are here

  • Home
  • Archive
  • Volume 11, Issue 10
  • AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: October 2023 to February 2026

AbstractFullPdf
Oct 202321882192170
Nov 2023319322128
Dec 202320921090
Jan 202410410760
Feb 202412112269
Mar 202412112278
Apr 202419619759
May 202410811050
Jun 2024999864
Jul 202412512866
Aug 2024787523
Sep 2024878740
Oct 2024939351
Nov 2024737435
Dec 202411011240
Jan 2025787849
Feb 2025727343
Mar 2025717044
Apr 2025909037
May 2025606144
Jun 2025424231
Jul 2025110
Aug 2025110
Feb 2026110
Total444744661271